Table 2B.
Distribution of antimicrobial resistance genes and point mutation in Campylobacter coli genomes according to their phenotypes as determined by disk diffusion testing
| Campylobacter coli (N = 67) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Resistance genes and point mutations | Quinolonesa (N = 67) | Macrolidesb (N = 67) | Tetracyclinesc (N = 67) | Aminoglycosidesd (N = 67) | Amoxicillin-clavulanic acid (N = 64) | Ampicillin (N = 53) | ||||||
| Resistant (N = 52) | Susceptible (N = 15) | Resistant (N = 30) | Susceptible (N = 37) | Resistant (N = 44) | Susceptible (N = 23) | Resistant (N = 25) | Susceptible (N = 42) | Resistant (N = 9) | Susceptible (N = 55) | Resistant (N = 36) | Susceptible (N = 17) | |
| MDR | ||||||||||||
| RE-cmeABC | 21.1% (11/52) | 6.7% (1/15) | 26.7% (8/30) | 10.8% (4/37) | 25.0% (11/44) | 4.3% (1/23) | 24.0% (6/25) | 14.3% (6/42) | 0% (0/9) | 21.8% (12/55) | 22.2% (8/36) | 0% (0/17) |
| Quinolones | ||||||||||||
| gyrA Thr86Ile | 96.2% (50/52) | 40.0% (6/15) | 100% (30/30) | 70.3% (26/37) | 95.5% (42/44) | 60.9% (14/23) | 100% (25/25) | 73.8% (31/42) | 100% (9/9) | 80.0% (44/55) | 94.4% (34/36) | 58.8% (10/17) |
| Macrolides | ||||||||||||
| 23S rRNA A2075G | 55.8% (29/52) | 26.7% (4/15) | 90.0% (27/30) | 16.2% (6/37) | 70.5% (31/44) | 8.7% (2/23) | 96% (24/25) | 21.4% (9/42) | 66.7% (6/9) | 43.6% (24/55) | 69.4% (25/36) | 0% (0/17) |
| Tetracyclines | ||||||||||||
| tet(O) | 75.0% (39/52) | 33.3% (5/15) | 100% (30/30) | 37.8% (14/37) | 93.2% (41/44) | 13.0% (3/23) | 100% (25/25) | 45.2% (19/42) | 88.9% (8/9) | 60.0% (33/55) | 86.1% (31/36) | 11.8% (2/17) |
| Aminoglycosides | ||||||||||||
| Any gene | 55.8% (29/52) | 26.7% (4/15) | 86.7% (26/30) | 18.9% (1/33) | 70.5% (31/44) | 8.7% (2/23) | 100% (25/25) | 19.0% (8/42) | 66.7% (6/9) | 43.6% (33/55) | 63.9% (23/36) | 0% (0/17) |
| aph(2′)-If | 5.8% (3/52) | 13.3% (2/15) | 3.3% (1/30) | 10.8% (4/37) | 6.8% (3/44) | 8.7% (2/23) | 8.0% (2/25) | 16.7% (7/42) | 0% (0/9) | 3.6% (2/55) | 0% (0/36) | 0% (0/17) |
| aph(3′)-IIIa | 53.8% (28/52) | 26.7% (4/15) | 83.3% (25/30) | 18.9% (7/37) | 68.2% (30/44) | 8.7% (2/23) | 100% (25/25) | 16.7% (7/42) | 66.7% (6/9) | 41.8% (23/55) | 61.1% (22/36) | 0% (0/17) |
| aad6 | 9.6% (5/52) | 26.7% (4/15) | 6.7% (2/30) | 18.9% (7/37) | 15.9% (7/44) | 8.7% (2/23) | 8.0% (2/25) | 16.7% (7/42) | 22.2% (2/9) | 7.3% (4/55) | 0% (0/36) | 0% (0/17) |
| aad9 | 7.7% (4/52) | 13.3% (2/15) | 6.7% (2/30) | 10.8% (4/37) | 9.1% (4/44) | 8.7% (2/23) | 12.0% (3/25) | 7.1% (3/42) | 11.1% (1/9) | 3.6% (2/55) | 0% (0/36) | 0% (0/17) |
| aadE | - | - | - | - | - | - | - | - | - | - | - | - |
| ant6-Ia | 9.6% (5/52) | 26.7% (4/15) | 6.7% (2/30) | 18.9% (7/37) | 15.9% (7/44) | 8.7% (2/23) | 8.0% (2/25) | 16.7% (7/42) | 22.2% (2/9) | 7.3% (4/55) | 0% (0/36) | 0% (0/17) |
| SAT4 | 7.7% (4/52) | 26.7% (4/15) | 3.3% (1/30) | 18.9% (7/37) | 13.6% (6/44) | 8.7% (2/23) | 4.00% (1/25) | 16.7% (7/42) | 11.1% (1/9) | 7.3% (4/55) | 0% (0/36) | 0% (0/17) |
| rpsL | 40.4% (21/52) | 0% (0/15) | 70.0% (21/30) | 0% (0/30) | 47.7% (21/44) | 0% (0/23) | 80.0% (20/25) | 2.4% (1/42) | 44.4% (4/9) | 30.9% (17/57) | 55.6% (20/36) | 0% (0/17) |
| Beta-lactams | ||||||||||||
| blaOXA genee | 96.2% (50/52) | 60.0% 9/15) | 100% (30/30) | 78.4% (29/37) | 97.7% (43/44) | 69.6% (16/23) | 100.0% (25/25) | 81.0% (34/42) | 100% (9/9) | 85.5% (47/55) | 97.2% (35/36) | 58.5% (10/17) |
| Active TATA boxf | 61.5% (32/52) | 33.3% (5/15) | 80.0% (24/30) | 35.1% (13/37) | 83.8% (31/37) | 26.1% (6/23) | 80.0% (20/25) | 40.5% (17/42) | 88.9% (8/9) | 47.3% (26/55) | 72.2% (26/36) | 0% (0/17) |
NOTE: Other mutations in the gyrA gene (Asp90Asn, Thr86Lys, Thr86Val, Thr86Ala and Asp90Tyr substitutions, and double mutations Thr86Ile-Pro104Ser and Thr86Ile-Asp90Asn), 23S rRNA genes (A2074G, A2075C), mutations in L4 and L22 ribosomal proteins, and ermB resistance gene were not found. bolded = resistance genes associated with phenotypic profile MDR, multidrug-resistant.
Includes susceptibility to CIP and NAL.
Includes susceptibility to AZM and ERY.
Includes susceptibility to TET.
Includes susceptibility to GEN.
All blaOXA genes belong to the blaOXA61 and blaOXA184 family.
G to T transversion represents an activation of the TATA box.